Amgen has acquired Dark Blue Therapeutics, a British biotech company, for $840 million to bolster its oncology pipeline with Dark Blue’s preclinical blood cancer program.
| Acquirer | Target | Value ($m) | Type | Closed on |
|---|---|---|---|---|
| Amgen (US) | Dark Blue Therapeutics (GB) | 840 | acquisition | 2026-01-06 |
The acquisition, announced on January 6, 2026, aims to strengthen Amgen's position in the blood cancer market by adding Dark Blue’s preclinical program targeting acute myeloid leukemia (AML). Dark Blue Therapeutics had been exploring a potential IPO amid an extended period of difficulty for British biotech firms securing public listings.
Amgen has acquired several oncology-focused companies over recent years, but this deal is particularly significant due to the potential clinical impact of Dark Blue’s program. The company's preclinical research offers a promising approach in treating AML that complements Amgen's existing therapeutic offerings and could provide new options for patients.
Dark Blue Therapeutics’ preclinical stage drug candidate has shown encouraging results in early-stage testing, highlighting the potential for rapid development post-acquisition. The deal includes an upfront payment of $600 million with up to $240 million in additional milestones tied to regulatory and commercial achievements.
The transaction was advised on by BofA Securities as sell-side advisor to Dark Blue Therapeutics, while legal counsel was provided by Goodwin Procter. Amgen’s own advisors were not disclosed.
With the acquisition of Dark Blue Therapeutics, Amgen is making a strategic move to enhance its oncology portfolio and expand its reach in blood cancer treatments. The deal underscores Amgen's commitment to innovation and collaboration with smaller biotech firms to drive advancements in patient care.